pipette
ENEnglish

Distinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants

Bo Zhang, Youyi Fong, Chenchen Yu, Shiyu Chen, Valentin Voillet, Bhavesh R. Borate, Katharine V. Schwedhelm, Zhe Chen, Jing Wang, Nadine Rouphael, Angela R Branche, David Joseph Diemert, Ann Regina Falsey, Daniel S. Graciaa, Lindsey Robert Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Satoshi Kamidani, Emmanuel B. Walter, Richard M. Novak, Richard E. Rupp, Lisa A. Jackson, Craig A. Magaret, Lindsay Nicole Carpp, Tara M Babu, Angelica C Kottkamp, Annie F. Luetkemeyer, Lilly Cheng Immergluck, Rachel M. Presti, Martín Bäcker, Patricia L. Winokur, Siham M. Mahgoub, Paul Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Jinjian Mu, Mat Makowski, Mamodikoe Makhene, Seema Nayak, Paul C. Roberts, Dean A. Follmann, Stephen C. De Rosa, M. Juliana McElrath, Peter B. Gilbert, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team

Revista con revisión por pares

En palabras de los autores

The relationship between SARS-CoV-2-specific T cell responses and COVID-19 risk is incompletely understood, particularly after variant-adapted booster receipt. We assessed Spike-specific and Nucleocapsid-specific CD4+ and CD8+ T cell responses, measured by validated 27-color intracellular cytokine staining assay, as correlates of COVID-19 risk over 6 months in COVAIL recipients of a second SARS-CoV-2 booster on Day 1 (D1). Among one-dose mRNA recipients, D15 CD4 + T cell IFN-γ and/or IL-2 Spike BA.4/5 responses correlated inversely with COVID-19 risk for previously-infected (non-naïve) [hazard ratio (HR) = 0.62 (95% CI 0.39, 0.99) per 3-fold increase], but not SARS-CoV-2 naïve [HR = 1.03 (0.81, 1.32)], participants (22 non-naïve, 122 naïve cases). Spike-specific CD4+ T cells and neutralizing antibodies each independently predicted COVID-19 in non-naïve participants [Cox bivariate model HRs per standard deviation: D1 Spike CD4 + T cell 0.81 (0.68, 0.96), D15 titer 0.43 (0.27, 0.69), co-correlatep < 0.001]. Among non-naïve participants, high Spike-specific CD4+ T cell responses and neutralizing antibody titers marked low risk, as did polyfunctional Spike-specific CD4+ T cells expressing ≥ three cytokine(s)/markers. At the same high D15 CD4+ Spike-specific T cell levels, risk was lower for non-naïve vs. naïve participants, suggesting that these T cell responses are a proxy for unmeasured protective immune mechanism(s) operant post-SARS-CoV-2 infection. Vaccines to SARS-CoV-2 clearly stimulate virus specific T cell and antibody responses but T cell-mediated protection is challenging to show. Here the authors use PBMC samples from an open-label clinical trial of different prototype and variant-specific COVID-19 vaccine boosters to examine the function and phenotype of T cell populations and how T cell response levels associate with risk of, and with protection against, symptomatic SARS-CoV-2 infection.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 8 de octubre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-78444-6